SMO and chronic myelogenous leukemia, BCR-ABL1 positive: Based on previous studies indicating that GLI1 is an appropriate biomarker for Hh pathway activity33, 34 and our own data showing up-regulation of GLI1 in both primary human and murine CP-CML LSC, we sought to assess the effect of SMO inhibition with LDE225 on GLI1 expression in CP-CML cells.